

Markella V Zanni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4651138/publications.pdf>

Version: 2024-02-01

76
papers

2,757
citations

257450

24
h-index

189892

50
g-index

76
all docs

76
docs citations

76
times ranked

3651
citing authors

#	ARTICLE	IF	CITATIONS
1	COVID-19 Vaccination Rates in a Global HIV Cohort. <i>Journal of Infectious Diseases</i> , 2022, 225, 603-607.	4.0	8
2	Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk. <i>Clinical Infectious Diseases</i> , 2022, 75, 1154-1163.	5.8	4
3	Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV. <i>Scientific Reports</i> , 2022, 12, 577.	3.3	27
4	Prevalence and Correlates of Electrocardiographic Abnormalities in Adults With HIV: Insights From the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 89, 349-359.	2.1	4
5	Sexual Dimorphism in Cardiovascular Biomarkers: Clinical and Research Implications. <i>Circulation Research</i> , 2022, 130, 578-592.	4.5	13
6	Factors Associated With Systemic Immune Activation Indices in a Global Primary Cardiovascular Disease Prevention Cohort of People With Human Immunodeficiency Virus on Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 2022, 75, 1324-1333.	5.8	8
7	Proteomic Signature of Subclinical Coronary Artery Disease in People With HIV: Analysis of the REPRIEVE Mechanistic Substudy. <i>Journal of Infectious Diseases</i> , 2022, 226, 1809-1822.	4.0	11
8	Chronic Human Immunodeficiency Virus Infection Is Associated with Accelerated Decline of Forced Expiratory Volume in 1 Second among Women but Not among Men: A Longitudinal Cohort Study in Uganda. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1779-1783.	3.2	4
9	Hot Flashes and Cardiovascular Disease Risk Indices Among Women With HIV. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab011.	0.9	1
10	Menopausal Symptoms and Cardiovascular Disease Risk Indices Among Women With HIV. <i>Journal of the Endocrine Society</i> , 2021, 5, A293-A294.	0.2	0
11	Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. <i>JAMA Network Open</i> , 2021, 4, e2114923.	5.9	38
12	Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, 2009-2022.	5.8	19
13	Cardiovascular Disease Risk Among Transgender People with HIV. <i>Current HIV/AIDS Reports</i> , 2021, 18, 407-423.	3.1	3
14	A Sex-Stratified Analysis of Monocyte Phenotypes Associated with HIV Infection in Uganda. <i>Viruses</i> , 2021, 13, 2135.	3.3	1
15	Assessment of Obesity and Cardiometabolic Status by Integrase Inhibitor Use in REPRIEVE: A Propensity-Weighted Analysis of a Multinational Primary Cardiovascular Prevention Cohort of People With Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab537.	0.9	19
16	Immune Correlates of Diffuse Myocardial Fibrosis and Diastolic Dysfunction Among Aging Women With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2020, 221, 1315-1320.	4.0	33
17	Amino-terminal Pro-B-Type Natriuretic Peptide Among Patients Living With Both Human Immunodeficiency Virus and Heart Failure. <i>Clinical Infectious Diseases</i> , 2020, 71, 1306-1315.	5.8	2
18	Brief Report: Vascular Dysfunction and Monocyte Activation Among Women With HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 233-238.	2.1	4

#	ARTICLE	IF	CITATIONS
19	Effects of Integrase Inhibitor-Based ART on the NLRP3 Inflammasome Among ART-Naïve People With HIV. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa459.	0.9	6
20	Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S8-S19.	4.0	8
21	Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S20-S30.	4.0	16
22	Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination. <i>HIV Research and Clinical Practice</i> , 2020, 21, 11-23.	1.1	5
23	Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. <i>Journal of Infectious Diseases</i> , 2020, 222, S31-S40.	4.0	4
24	Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. <i>Journal of Infectious Diseases</i> , 2020, 222, S63-S69.	4.0	17
25	Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. <i>Obesity</i> , 2020, 28, 749-755.	3.0	9
26	Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. <i>Journal of Infectious Diseases</i> , 2020, 222, 929-939.	4.0	16
27	Caspase-1 Activation Is Related With HIV-Associated Atherosclerosis in an HIV Transgenic Mouse Model and HIV Patient Cohort. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1762-1775.	2.4	20
28	Conceptualizing the Risks of Coronary Heart Disease and Heart Failure Among People Aging with HIV: Sex-Specific Considerations. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2019, 21, 41.	0.9	12
29	Intramyocardial Triglycerides Among Women With vs Without HIV: Hormonal Correlates and Functional Consequences. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 6090-6100.	3.6	21
30	Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations. <i>Current HIV/AIDS Reports</i> , 2019, 16, 371-380.	3.1	26
31	Sex Differences in Circulating Biomarkers of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1543-1553.	2.8	82
32	The Risk for Sudden Cardiac Death Among Patients Living With Heart Failure and Human Immunodeficiency Virus. <i>JACC: Heart Failure</i> , 2019, 7, 759-767.	4.1	25
33	Heart failure and adverse heart failure outcomes among persons living with HIV in a US tertiary medical center. <i>American Heart Journal</i> , 2019, 210, 39-48.	2.7	23
34	Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. <i>American Heart Journal</i> , 2019, 212, 1-12.	2.7	43
35	Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). <i>American Heart Journal</i> , 2019, 212, 23-35.	2.7	99
36	Reply. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e84-e85.	2.1	0

#	ARTICLE	IF	CITATIONS
37	Striving to characterize endocrineâ€“metabolic and immune health risks among transgender women with HIV. <i>Aids</i> , 2019, 33, 919-922.	2.2	1
38	Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV. <i>Aids</i> , 2019, 33, 229-236.	2.2	18
39	Novel mediators of statin effects on plaque in HIV. <i>Aids</i> , 2018, 32, 867-876.	2.2	9
40	Sleep Apnea and Heart Failure With a Reduced Ejection Fraction Among Persons Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2018, 67, 447-455.	5.8	2
41	Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 421-428.	2.1	18
42	Elevated ischemic stroke risk among women living with HIV infection. <i>Aids</i> , 2018, 32, 59-67.	2.2	58
43	Cardiovascular Risk Profile of Transgender Women With HIV: A US Health Care Database Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, e39-e41.	2.1	14
44	Incidence, Predictors, and Outcomes of Implantable Cardioverterâ€“Defibrillator Discharge Among People Living With HIV. <i>Journal of the American Heart Association</i> , 2018, 7, e009857.	3.7	11
45	Impact of the American College of Cardiology/American Heart Association Cholesterol Guidelines on Statin Eligibility Among Human Immunodeficiency Virus-Infected Individuals. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy326.	0.9	7
46	Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. <i>EBioMedicine</i> , 2018, 35, 58-66.	6.1	16
47	Protease Inhibitors and Cardiovascular Outcomes in Patients With HIV and Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 72, 518-530.	2.8	68
48	The Association of Obesity and Cardiometabolic Traits With Incident HFpEF and HFrEF. <i>JACC: Heart Failure</i> , 2018, 6, 701-709.	4.1	254
49	HIV Infection and Heart Failure Outcomes in Women. <i>Journal of the American College of Cardiology</i> , 2017, 69, 107-108.	2.8	49
50	Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. <i>HIV Clinical Trials</i> , 2017, 18, 83-91.	2.0	14
51	Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. <i>Aids</i> , 2017, 31, 797-806.	2.2	74
52	Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV-Infected Individuals. <i>Journal of Infectious Diseases</i> , 2017, 215, 1264-1269.	4.0	33
53	Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation. <i>Current HIV/AIDS Reports</i> , 2017, 14, 220-228.	3.1	49
54	Presence, Characteristics, and Prognostic Associations of Carotid Plaque Among People Living With HIV. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	20

#	ARTICLE	IF	CITATIONS
55	Cardiovascular disease risk among women living with HIV in North America and Europe. <i>Current Opinion in HIV and AIDS</i> , 2017, 12, 585-593.	3.8	43
56	Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. <i>Antiviral Therapy</i> , 2017, 23, 1-9.	1.0	11
57	Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx227.	0.9	17
58	HDL Cholesterol Efflux Capacity in Newly Diagnosed HIV and Effects of Antiretroviral Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4250-4259.	3.6	6
59	Aspartame Intake Relates to Coronary Plaque Burden and Inflammatory Indices in Human Immunodeficiency Virus. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx083.	0.9	5
60	Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection. <i>JAMA Cardiology</i> , 2016, 1, 474.	6.1	66
61	Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals. <i>Aids</i> , 2016, 30, 2205-2214.	2.2	25
62	Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV. <i>Aids</i> , 2015, 30, 1.	2.2	31
63	Increased Arterial Inflammation Relates to High-Risk Coronary Plaque Morphology in HIV-Infected Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2014, 66, 164-171.	2.1	66
64	2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. <i>Aids</i> , 2014, 28, 2061-2070.	2.2	65
65	Risk of coronary heart disease in patients with HIV infection. <i>Nature Reviews Cardiology</i> , 2014, 11, 728-741.	13.7	90
66	Hdl Redox Activity is Increased in HIV-Infected Men in Association with Macrophage Activation and Non-Calcified Coronary Atherosclerotic Plaque. <i>Antiviral Therapy</i> , 2014, 19, 805-811.	1.0	16
67	Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. <i>Aids</i> , 2013, 27, 1263-1272.	2.2	115
68	Arterial Inflammation in Patients With HIV. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 379.	7.4	411
69	Increased FDG uptake in association with reduced extremity fat in HIV patients. <i>Antiviral Therapy</i> , 2012, 18, 243-248.	1.0	14
70	Relationship between monocyte/macrophage activation marker soluble CD163 and insulin resistance in obese and normal-weight subjects. <i>Clinical Endocrinology</i> , 2012, 77, 385-390.	2.4	67
71	HIV-Specific Immune Dysregulation and Atherosclerosis. <i>Current HIV/AIDS Reports</i> , 2012, 9, 200-205.	3.1	34
72	Estrogen Sulfotransferase Is Expressed in Subcutaneous Adipose Tissue of Obese Humans in Association with TNF- α and SOCS3. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1153-E1158.	3.6	14

#	ARTICLE	IF	CITATIONS
73	TNF- α Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E146-E150.	3.6	281
74	Effects of TNF- α antagonism on E-selectin in obese subjects with metabolic dysregulation. <i>Clinical Endocrinology</i> , 2010, 73, 48-54.	2.4	19
75	Contribution of the Hormone-Response Elements of the Proximal ApoA-I Promoter, ApoCIII Enhancer, and C/EBP Binding Site of the Proximal ApoA-I Promoter to the Hepatic and Intestinal Expression of the ApoA-I and ApoCIII Genes in Transgenic Mice. <i>Biochemistry</i> , 2004, 43, 5084-5093.	2.5	12
76	Regulatory Gene Mutations Affecting Apolipoprotein Gene Expression: Functions and Regulatory Behavior of Known Genes May Guide Future Pharmacogenomic Approaches to Therapy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 411-24.	2.3	3